OncoMatch/Clinical Trials/NCT07349537
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Is NCT07349537 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including RMC-5127 and daraxonrasib for non-small cell lung cancer (nsclc).
Treatment: RMC-5127 · daraxonrasib · cetuximab — The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Pancreatic Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS g12v
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy (including targeted therapy) appropriate for tumor type and stage
Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
Cannot have received: KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and/or inhibitors)
Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and/or inhibitors)
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate kidney function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- START Midwest · Grand Rapids, Michigan
- NEXT - Dallas · Dallas, Texas
- NEXT · San Antonio, Texas
- START - San Antonio · San Antonio, Texas
- NEXT - Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify